Thomas A Weppelmann1, Michael E von Fricken2, Brandon Lam3, Taina Telisma4, Alexandre Existe5, Jean F Lemoine6, Joseph Larkin7, Bernard A Okech8. 1. Department of Environmental and Global Health, University of Florida, Gainesville, FL, United States; Emerging Pathogens Institute, University of Florida, Gainesville, FL, United States. Electronic address: riptos@ufl.edu. 2. Department of Environmental and Global Health, University of Florida, Gainesville, FL, United States; Emerging Pathogens Institute, University of Florida, Gainesville, FL, United States. Electronic address: Michaelvonfricken@epi.ufl.edu. 3. Emerging Pathogens Institute, University of Florida, Gainesville, FL, United States; Department of Microbiology and Cell Science, University of Florida, Gainesville, FL, United States. Electronic address: bran2805@ufl.edu. 4. Christianville Foundation, Christianville Boulevard Mareshall, Gressier, Haiti. Electronic address: tainaquisqueya@gmail.com. 5. Laboratoire National de Santé Publique, Ministère de la Santé Publique et de la Population, Port-au-Prince, Haiti. Electronic address: alexandre.existe@gmail.com. 6. Programme National de Controle de la Malaria, Ministère de la Santé Publique et de la Population, Port-au-Prince, Haiti. Electronic address: tileum@hotmail.com. 7. Department of Microbiology and Cell Science, University of Florida, Gainesville, FL, United States. Electronic address: jlarkin3@ufl.edu. 8. Department of Environmental and Global Health, University of Florida, Gainesville, FL, United States; Emerging Pathogens Institute, University of Florida, Gainesville, FL, United States. Electronic address: bokech@ufl.edu.
Abstract
BACKGROUND: Plasmodium vivax infections, while quite prevalent throughout South and Central America, are virtually non-existent in Haiti, where P. falciparum infections are detected in over 99% of malaria cases. Historically, few cases of P. vivax have been reported in Haiti; all of which were identified by microscopy and none were confirmed by molecular diagnostics. To further examine the transmission of P. vivax in Haiti, a cross-sectional seroepidemiological study was conducted. METHODS: Whole blood was collected from 814 community members and school children ranging in age between 2 and 80 years-of-age from four locations in the Ouest and Sud-Est Departments of Haiti. After separation of serum, samples were screened for antibodies toward P. vivax apical membrane antigen (AMA-1) and merozoite surface protein-119 (MSP-1) using an indirect enzyme-linked immunosorbent assay (ELISA). RESULTS: Of all participants screened, 4.42% (36/814) were seropositive for AMA-1, 4.55% (37/814) were seropositive for MSP-1, 7.99% (65/814) were seropositive to either antigen, and only 0.98% (7/814) were seropositive for both antigens. Seroconversion rates (SCR) for AMA-1, MSP-1, either AMA-1 or MSP-1, and for both AMA-1 and MSP-1 estimated from the cross-sectional seroprevalence indicated rates of P. vivax transmission of less than 1% per year. CONCLUSION: Given the lack of historical evidence of P. vivax infections on the island of Hispaniola, the sparse serological evidence of antibodies toward P. vivax identified in the current study further support the notion that the transmission of P. vivax malaria might be extremely low or even completely absent in Haiti.
BACKGROUND:Plasmodium vivaxinfections, while quite prevalent throughout South and Central America, are virtually non-existent in Haiti, where P. falciparum infections are detected in over 99% of malaria cases. Historically, few cases of P. vivax have been reported in Haiti; all of which were identified by microscopy and none were confirmed by molecular diagnostics. To further examine the transmission of P. vivax in Haiti, a cross-sectional seroepidemiological study was conducted. METHODS: Whole blood was collected from 814 community members and school children ranging in age between 2 and 80 years-of-age from four locations in the Ouest and Sud-Est Departments of Haiti. After separation of serum, samples were screened for antibodies toward P. vivax apical membrane antigen (AMA-1) and merozoite surface protein-119 (MSP-1) using an indirect enzyme-linked immunosorbent assay (ELISA). RESULTS: Of all participants screened, 4.42% (36/814) were seropositive for AMA-1, 4.55% (37/814) were seropositive for MSP-1, 7.99% (65/814) were seropositive to either antigen, and only 0.98% (7/814) were seropositive for both antigens. Seroconversion rates (SCR) for AMA-1, MSP-1, either AMA-1 or MSP-1, and for both AMA-1 and MSP-1 estimated from the cross-sectional seroprevalence indicated rates of P. vivax transmission of less than 1% per year. CONCLUSION: Given the lack of historical evidence of P. vivaxinfections on the island of Hispaniola, the sparse serological evidence of antibodies toward P. vivax identified in the current study further support the notion that the transmission of P. vivaxmalaria might be extremely low or even completely absent in Haiti.
Authors: Thomas A Weppelmann; Michael E von Fricken; Tara D Wilfong; Elisa Aguenza; Taina T Philippe; Bernard A Okech Journal: Am J Trop Med Hyg Date: 2017-08-18 Impact factor: 2.345
Authors: Camelia Herman; Curtis S Huber; Sophie Jones; Laura Steinhardt; Mateusz M Plucinski; Jean F Lemoine; Michelle Chang; John W Barnwell; Venkatachalam Udhayakumar; Eric Rogier Journal: Malar J Date: 2019-11-27 Impact factor: 2.979
Authors: Sonal Kale; Chander P Yadav; Pavitra N Rao; Sneh Shalini; Alex Eapen; Harish C Srivasatava; Surya K Sharma; Veena Pande; Jane M Carlton; Om P Singh; Prashant K Mallick Journal: Malar J Date: 2019-12-16 Impact factor: 2.979
Authors: Jean Ricardo Jules; Jeronimo Alencar; Martha Cecília Suárez-Mutis; Ernst Jn Baptiste; Hermano de Albuquerque; Maria Goreti Rosa-Freitas; Christian Raccurt; Ricardo Lourenço de Oliveira; Teresa Fernandes Silva-do-Nascimento Journal: Rev Soc Bras Med Trop Date: 2022-02-25 Impact factor: 1.581